comparemela.com

Latest Breaking News On - International prognostic index - Page 2 : comparemela.com

Biosimilar HLX01 Demonstrates Bioequivalence With Rituxan in DLBCL

A new study has found that HLX01 (HanliKang), a rituximab biosimilar, had comparable overall survival and progression-free survival rates to the reference product (Rituxan) in patients with diffuse large B-cell lymphoma (DLBCL).

Recent Approvals Across Hematologic Malignancies Usher in a New Era

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.